Longevity & AgingResearch PaperPaywall

Blocking EZH2 in injured kidneys slowed senescence and scarring in mice

In mice, the EZH2 inhibitor DZNep curbed tubular senescence and fibrosis after kidney injury, pointing to an EZH2-HIF-1α pathway behind the shift from AKI to CKD.

Tuesday, November 17, 2026 0 views
Published in Life Sci
a pathologist's microscope slide of scarred kidney tissue stained blue and pink beside a mouse kidney specimen in a lab

Summary

A single episode of acute kidney injury can leave the kidney scarred and slowly failing, and aged cells that stop dividing but stay active appear to drive part of that process. This mouse and cell study looked at two proteins, EZH2 and HIF-1α, that stayed elevated after the kidneys were deprived of blood flow and then reperfused. Mice treated with the EZH2 inhibitor DZNep had better kidney function, less tubular damage, less fibrosis and fewer signs of cellular senescence. In human kidney tubular cells exposed to low oxygen and reoxygenation, lowering EZH2 reduced HIF-1α and inflammatory senescence signals, and lowering HIF-1α reduced EZH2 and scarring-related proteins. The authors stress the data do not prove direct regulation or a feedback loop. The work suggests this pathway may be a future target for preventing the move from acute to chronic kidney disease.

Detailed Summary

Acute kidney injury (AKI) is common, and survivors face a higher risk of chronic kidney disease (CKD) later. One proposed bridge between the two is maladaptive repair, in which damaged tubular cells become senescent: they stop dividing but secrete inflammatory and profibrotic factors, known as the senescence-associated secretory phenotype (SASP). Because kidney function declines with age and senescent cells accumulate in older kidneys, understanding what drives this process matters for healthspan.

This study examined two regulators, the epigenetic enzyme EZH2 and the hypoxia-responsive factor HIF-1α. Researchers used a mouse model of unilateral ischemia-reperfusion injury combined with removal of the other kidney to follow progression from AKI to CKD. They gave some animals DZNep, a pharmacological EZH2 inhibitor. In parallel, they used human kidney tubular epithelial cells (HK-2) exposed to hypoxia/reoxygenation or TGF-β1, and tested DZNep and 2-MeOE2, a compound that inhibits HIF-1α.

EZH2 and HIF-1α stayed elevated after ischemic injury. DZNep improved kidney function and reduced tubular damage, fibrosis and markers of senescence. In cells, both inhibitors dampened injury, fibrosis and senescence responses. Genetic knockdown of EZH2 reduced HIF-1α expression, SASP production and accumulation of the scarring proteins α-SMA and fibronectin. Knockdown of HIF1A likewise lowered EZH2 and the same SASP and profibrotic signals after hypoxia/reoxygenation.

Taken together, the findings suggest EZH2- and HIF-1α-linked signaling contributes to tubular senescence and fibrotic remodeling after AKI. This could make the pathway a candidate target for slowing the AKI-to-CKD transition, and it adds to evidence linking epigenetic regulation to senescence.

Caveats are important. The authors themselves note that the genetic data do not establish direct regulation or a feedback loop, and they call for further mechanistic work. The evidence comes from mice and cultured cells, so human benefit is unproven. DZNep is a broad research compound, not an approved therapy. This summary is based on the abstract only.

Key Findings

  • EZH2 and HIF-1α stayed elevated in mouse kidneys after ischemia-reperfusion injury.
  • The EZH2 inhibitor DZNep improved kidney function and reduced tubular damage, fibrosis and senescence markers in mice.
  • EZH2 knockdown in kidney cells lowered HIF-1α, SASP production and the scarring proteins α-SMA and fibronectin.
  • HIF1A knockdown reduced EZH2 and profibrotic signals, but direct regulation or a feedback loop was not shown.

Methodology

Researchers used a mouse unilateral ischemia-reperfusion model with contralateral nephrectomy to follow AKI-to-CKD progression, with or without DZNep. Complementary experiments used HK-2 tubular cells under hypoxia/reoxygenation or TGF-β1, with pharmacological inhibitors and EZH2 or HIF1A knockdown.

Study Limitations

This summary is based on the abstract only, so sample sizes, statistics and effect sizes were unavailable. Findings come from mouse and cell models, and the authors state that direct regulation and feedback between EZH2 and HIF-1α were not established. DZNep and 2-MeOE2 may have off-target effects.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: